Cargando…

Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation

BACKGROUND: Human γδ T cells expressing Vγ2Vδ2 T cell receptors monitor foreign- and self-prenyl pyrophosphate metabolites in isoprenoid biosynthesis to mediate immunity to microbes and tumors. Adoptive immunotherapy with Vγ2Vδ2 T cells has been used to treat cancer patients with partial and complet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nada, Mohanad H., Wang, Hong, Workalemahu, Grefachew, Tanaka, Yoshimasa, Morita, Craig T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319075/ https://www.ncbi.nlm.nih.gov/pubmed/28239463 http://dx.doi.org/10.1186/s40425-017-0209-6

Ejemplares similares

PD-1 checkpoint blockade enhances adoptive immunotherapy by human Vγ2Vδ2 T cells against human prostate cancer
por: Nada, Mohanad H., et al.
Publicado: (2021)

Comparison of a Novel Bisphosphonate Prodrug and Zoledronic Acid in the Induction of Cytotoxicity in Human Vγ2Vδ2 T Cells
por: Okuno, Daisuke, et al.
Publicado: (2020)

CAR-Modified Vγ9Vδ2 T Cells Propagated Using a Novel Bisphosphonate Prodrug for Allogeneic Adoptive Immunotherapy
por: Wang, Yizheng, et al.
Publicado: (2023)

TGF-β1 potentiates Vγ9Vδ2 T cell adoptive immunotherapy of cancer
por: Beatson, Richard E., et al.
Publicado: (2021)

Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate
por: SUGAI, SHIORI, et al.
Publicado: (2016)

Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer
por: Hoeres, Timm, et al.
Publicado: (2018)

Releasing the restraints of Vγ9Vδ2 T-cells in cancer immunotherapy
por: Ridgley, Laura A., et al.
Publicado: (2023)

Expansion of human γδ T cells for adoptive immunotherapy using a bisphosphonate prodrug
por: Tanaka, Yoshimasa, et al.
Publicado: (2018)

Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer
por: Wada, Ikuo, et al.
Publicado: (2014)

Vγ9Vδ2 T-cell immunotherapy in blood cancers: ready for prime time?
por: Giannotta, Claudia, et al.
Publicado: (2023)

Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study
por: Kakimi, Kazuhiro, et al.
Publicado: (2020)

Adjunctive Zoledronate + IL-2 administrations enhance anti-tuberculosis Vγ2Vδ2 T-effector populations, and improve treatment outcome of multidrug-resistant tuberculosis(1)
por: Shen, Hongbo, et al.
Publicado: (2022)

Nanoformulated Zoledronic Acid Boosts the Vδ2 T Cell Immunotherapeutic Potential in Colorectal Cancer
por: Di Mascolo, Daniele, et al.
Publicado: (2019)

Beneficial Effect of Antibiotics and Microbial Metabolites on Expanded Vδ2Vγ9 T Cells in Hepatocellular Carcinoma Immunotherapy
por: Han, Jiajia, et al.
Publicado: (2020)

Sensing of Pyrophosphate Metabolites by Vγ9Vδ2 T Cells
por: Gu, Siyi, et al.
Publicado: (2015)

Role of Vγ9vδ2 T lymphocytes in infectious diseases
por: Gay, Laetitia, et al.
Publicado: (2022)

Mapping of γ/δ T cells reveals Vδ2+ T cells resistance to senescence
por: Xu, Weili, et al.
Publicado: (2018)

Mistletoe-Extract Drugs Stimulate Anti-Cancer Vγ9Vδ2 T Cells
por: Ma, Ling, et al.
Publicado: (2020)

Phenotype and functional changes of Vγ9/Vδ2 T lymphocytes in Behçet's disease and the effect of infliximab on Vγ9/Vδ2 T cell expansion, activation and cytotoxicity
por: Accardo-Palumbo, Antonina, et al.
Publicado: (2010)

Preferential Infiltration of Unique Vγ9Jγ2-Vδ2 T Cells Into Glioblastoma Multiforme
por: Lee, Mijeong, et al.
Publicado: (2019)

Development and Selection of the Human Vγ9Vδ2(+) T-Cell Repertoire
por: Willcox, Carrie R., et al.
Publicado: (2018)

The PPARα pathway in Vγ9Vδ2 T cell anergy
por: Poupot, Mary, et al.
Publicado: (2014)

Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma
por: Alnaggar, Mohammed, et al.
Publicado: (2019)

Preferential Th1 Cytokine Profile of Phosphoantigen-Stimulated Human Vγ9Vδ2 T Cells
por: Dunne, Margaret R., et al.
Publicado: (2010)

Characteristics of peripheral Vγ2Vδ2 T cells in interferon-γ release assay negative pulmonary tuberculosis patients
por: Yan, Liping, et al.
Publicado: (2018)

Role of Vγ9Vδ2+ γδ T cells in juvenile idiopathic arthritis
por: Gerstein, M, et al.
Publicado: (2008)

BTLA, a key regulator of Vγ9Vδ2 T-cell proliferation
por: Gertner-Dardenne, Julie, et al.
Publicado: (2013)

An Update on the Molecular Basis of Phosphoantigen Recognition by Vγ9Vδ2 T Cells
por: Herrmann, Thomas, et al.
Publicado: (2020)

The human Vδ2(+) T-cell compartment comprises distinct innate-like Vγ9(+) and adaptive Vγ9(-) subsets
por: Davey, Martin S., et al.
Publicado: (2018)

Human Vγ9Vδ2 T Lymphocytes in the Immune Response to P. falciparum Infection
por: Howard, Jennifer, et al.
Publicado: (2018)

Functional Phenotypes of Human Vγ9Vδ2 T Cells in Lymphoid Stress Surveillance
por: Nussbaumer, Oliver, et al.
Publicado: (2020)

Effector Vγ9Vδ2 T cell response to congenital Toxoplasma gondii infection
por: Ma, Ling, et al.
Publicado: (2021)

Generation and application of TGFβ-educated human Vγ9Vδ2 T cells
por: Parente-Pereira, Ana C., et al.
Publicado: (2022)

Zoledronate Triggers Vδ2 T Cells to Destroy and Kill Spheroids of Colon Carcinoma: Quantitative Image Analysis of Three-Dimensional Cultures
por: Varesano, Serena, et al.
Publicado: (2018)

Large-scale expansion of γδ T cells and peptide-specific cytotoxic T cells using zoledronate for adoptive immunotherapy
por: YOSHIKAWA, TOSHIAKI, et al.
Publicado: (2014)

Adoptive immunotherapy for gastric cancer using zoledronate-activated killer cells: A prospective observational study
por: Yamaguchi, Yoshiyuki, et al.
Publicado: (2020)

Adoptive immunotherapy for gastric cancer using zoledronate-activated killer cells: A prospective observational study
por: Yamaguchi, Yoshiyuki, et al.
Publicado: (2022)

Control of CD56 expression and tumor cell cytotoxicity in human Vγ2Vδ2 T cells
por: Urban, Elizabeth M, et al.
Publicado: (2009)

Vγ2 x PD-L1, a Bispecific Antibody Targeting Both the Vγ2 TCR and PD-L1, Improves the Anti-Tumor Response of Vγ2Vδ2 T Cell
por: Yang, Rui, et al.
Publicado: (2022)

Combined chemotherapy and allogeneic human Vγ9Vδ2 T lymphocyte-immunotherapies efficiently control the development of human epithelial ovarian cancer cells in vivo
por: Joalland, Noémie, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_efsa0bftum0cd1l3vhh0n21lev